Related Experiment Video

Updated: Jun 13, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

The relationship between angiotensin converting enzyme gene I/D polymorphism and QT dispersion in patients with

Cansin Tulunay Kaya1, Adalet Gurlek, Timucin Altin

  • 1Departments of Cardiology, Ankara University School of Medicine, Ankara, Turkey.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|May 19, 2010
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is linked to increased QT dispersion (QTd). Patients with the angiotensin-converting enzyme (ACE) DD genotype show even greater QTd, suggesting a genetic link to cardiac repolarization abnormalities in HCM.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) involves disorganized myocardial architecture, potentially leading to ventricular arrhythmias and sudden cardiac death.
  • The angiotensin-converting enzyme (ACE) DD genotype is hypothesized to correlate with increased myocardial collagen.
  • QT dispersion (QTd) assesses regional ventricular repolarization differences.

Purpose of the Study:

  • To investigate QT dispersion (QTd) in hypertrophic cardiomyopathy (HCM) patients and controls.
  • To examine the association between ACE genotypes and QTd in HCM and control groups.

Main Methods:

  • Sixty-three HCM patients and 20 healthy controls were enrolled.
  • QT parameters were measured using 12-lead electrocardiograms.
  • ACE genotypes were determined via polymerase chain reaction (PCR) from DNA.

Main Results:

  • QTd and corrected QTd (QTcd) were significantly elevated in HCM patients compared to controls.
  • While QTd did not vary by genotype in controls, HCM patients with the ACE DD genotype exhibited significantly greater QTd and QTcd than other genotypes.
  • Genotype frequencies were comparable between HCM and control groups.

Conclusions:

  • QTd and QTcd are elevated in hypertrophic cardiomyopathy (HCM) patients.
  • The ACE DD genotype is specifically associated with increased QTd and QTcd in HCM patients, highlighting a potential genetic influence on cardiac repolarization.
Abstract

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...